---
title: "Wedbush 表示，WAVE 生命科学的 ATS 数据可能会支持其 RNA 编辑平台"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/286602718.md"
description: "Wedbush Securities 预计 Wave Life Sciences 将在 2026 年 ATS 会议上展示其 RestorAATion-2 研究的数据，这可能会增强市场对其 RNA 编辑平台的信心。结果可能表明编辑效率的提高和持续的蛋白质反应，支持 α-1 抗胰蛋白酶的生产。尽管股价下跌 2.6% 至 6.72 美元，Wedbush 仍维持对 Wave Life Sciences 的 “跑赢大盘” 评级，目标价为 15 美元"
datetime: "2026-05-15T18:40:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286602718.md)
  - [en](https://longbridge.com/en/news/286602718.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286602718.md)
---

# Wedbush 表示，WAVE 生命科学的 ATS 数据可能会支持其 RNA 编辑平台

02:40 PM EDT, 05/15/2026 (MT Newswires) -- Wave Life Sciences ( WVE ) is expected to present new data from its RestorAATion-2 study of WVE-006 at the ATS 2026 conference that could further strengthen confidence in its RNA editing platform, Wedbush Securities said in a note Friday.

The brokerage said in a Friday research note that the upcoming results could show a consistent improvement pattern versus earlier cohorts, including higher editing efficiency and sustained protein responses across dose groups.

The investment firm added that the data may support clinically meaningful levels of alpha-1 antitrypsin production. It added that the durability of the response could enable monthly or less frequent dosing intervals.

Wedbush has an outperform rating and a $15 price target on Wave Life Sciences ( WVE ).

Shares of the company were down 2.6% in Friday trading.

Price: 6.72, Change: -0.18, Percent Change: -2.61

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

### 相关股票

- [WVE.US](https://longbridge.com/zh-CN/quote/WVE.US.md)
- [PBE.US](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/zh-CN/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [BBC.US](https://longbridge.com/zh-CN/quote/BBC.US.md)
- [ARKG.US](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/zh-CN/quote/BBH.US.md)

## 相关资讯与研究

- [CAR-T 迎接新时代](https://longbridge.com/zh-CN/news/286999381.md)
- [创胜集团医药-B 合作伙伴 INHIBRX 报告 OZEKIBART 的 CRC 最新积极数据并宣布就治疗软骨肉瘤提交美国 BLA 申请](https://longbridge.com/zh-CN/news/287126678.md)
- [百时美施贵宝向 3 万名员工全面开放 Anthropic 公司 Claude](https://longbridge.com/zh-CN/news/287085684.md)
- [制药巨头集体拥抱 AI 智能体：百时美施贵宝向 3 万员工推广 Claude](https://longbridge.com/zh-CN/news/287074661.md)
- [默沙东 ADC 药物达 III 期主要终点](https://longbridge.com/zh-CN/news/286929703.md)